A Phase 2 Proof of Concept Study to Evaluate the Efficacy, Safety and Pharmacokinetics of the HDAC Inhibitor 4SC-201 in Patients With Relapsed or Refractory Hodgkin's Lymphoma.

Trial Profile

A Phase 2 Proof of Concept Study to Evaluate the Efficacy, Safety and Pharmacokinetics of the HDAC Inhibitor 4SC-201 in Patients With Relapsed or Refractory Hodgkin's Lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Dec 2016

At a glance

  • Drugs Resminostat (Primary)
  • Indications Hodgkin's disease
  • Focus Proof of concept; Therapeutic Use
  • Acronyms SAPHIRE
  • Sponsors 4SC
  • Most Recent Events

    • 02 Dec 2016 Results of biomarker analysis from SHELTER,SAPHIRE and SHORE trials presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
    • 06 May 2014 Results published in an 4SC media release.
    • 15 Jun 2013 Planned number of patients changed from 33 to 45 as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top